Effectiveness of Ultrasound (US) Guided Supraclavicular Block

Effectiveness of Ultrasound Guided Supraclavicular Brachial Plexus Block With 20, 30, or 40 ml of Ropivacaine 0.5%

Status

Withdrawn

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00923494

Enrollment

Registered

2009-06-18

Start date

2009-05-31

Completion date

2010-12-31

Last updated

2017-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Analgesia, Pain

Keywords

Anesthesia

Brief summary

This research study is being done in order to find out if there is any difference in the effectiveness of ultrasound guided supraclavicular brachial plexus nerve block that can be achieved with 3 different amounts of ropivacaine 0.5% (20 ml, 30 ml, and 40 ml). The investigators want to show if you can have a successful nerve block with less amount of local anesthetic, thus potentially decreasing the risk of side effects.

Interventions

DRUG20 ml of ropivacaine 0.5%

Patient will receive 20 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.

DRUG30 ml of ropivacaine 0.5%

Patient will receive 30 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.

DRUG40 ml of ropivacaine 0.5%

Patient will receive 40 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to 64 Years

Healthy volunteers

Inclusion criteria

* Patients between the ages of 18-64, * Patients who are ASA I-III, presenting for distal upper extremity surgery. Surgeries to be considered are ORIF of distal upper extremity fractures such as ORIF radius, ORIF ulna, ORIF of any bones in the wrist or hand, and distal upper extremity surgery involving bones or tendons for which postoperative pain is to be expected. No emergency surgeries will be considered.

Exclusion criteria

* Emergency surgery, * Patient or surgeon refusal * Patients for which peripheral nerve block or study medications are contraindicated, * Patients on chronic analgesic therapy at home, * History of nerve injury, neuropathy, or known neurologic injury or illness, or inability to properly describe postoperative pain to investigators (language barrier, psychiatric disorder, dementia).

Design outcomes

Primary

Measure	Time frame
Onset of analgesia	First 30 minutes
Duration of analgesia	24 hours

Secondary

Measure	Time frame
Total analgesic use	First 24 hours

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026